This is a working overview of Tesamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Replacing natural polyunsaturated fatty acids (PUFA) with deuterated PUFA (dPUFA), which have deuterium in place of the bis-allylic hydrogens, can prevent cell death induced by erastin or RSL3. These deuterated PUFAs effectively inhibit ferroptosis and various chronic degenerative diseases associated with ferroptosis. Live-cell imaging has been used to observe the morphological changes that cells undergo during ferroptosis. Initially the cell contracts and then begins to swell. Perinuclear lipid assembly is observed immediately before ferroptosis occurs. After the process is complete, lipid droplets are redistributed throughout the cell (see GIF on right side).
== Structural properties == Traditionally, PPII has been considered to be relatively rigid and used as a "molecular ruler" in structural biology, e.g., to calibrate FRET efficiency measurements. However, subsequent experimental and theoretical studies have called into question this picture of a polyproline peptide as a "rigid rod". Further studies using terahertz spectroscopy and density functional theory calculations highlighted that polyproline is in fact much less rigid than originally thought. Interconversions between the PPII and PPI helix forms of poly-proline are slow, due to the high activation energy of X-Pro cis-trans isomerization (Ea ≈ 20 kcal/mol); however, this interconversion may be catalyzed by specific isomerases known as prolyl isomerases or PPIases. The interconversion between the PPII and PPI helices involve the cis-trans peptide bond isomerization along the whole peptide chain. Studies based on ion-mobility spectrometry revealed existence of a defined set of intermediates along this process.
=== Toponyms === Presently it is relatively easy to characterise a specific antithrombin genetic mutation. However prior to the use of modern characterisation techniques investigators named mutations for the town or city where the individual suffering from the deficiency resided i.e. the antithrombin mutation was designated a toponym. Modern mutational characterisation has since shown that many individual antithrombin toponyms are actually the result of the same genetic mutation, for example antithrombin-Toyama, is equivalent to antithrombin-Kumamoto, -Amien, -Tours, -Paris-1, -Paris-2, -Alger, -Padua-2 and -Barcelona.
== Clinical Relevance == Despite normally being a commensal organism, C. xerosis has been linked to many different opportunistic infections in humans and animals, including endocarditis, sepsis, abscesses, and osteomyelitis. However, it is possible that many early reports of this bacterium may have been cases of misidentification: a 1996 study found that out of 25 clinical isolates originally identified as C. xerosis, all were actually Corynebacterium amycolatum based on a number of biochemical tests which came back as different from the C. xerosis reference strain. Similarly, there is also evidence that some infections attributed to C. xerosis may have been caused by Corynebacterium striatum. Therefore, it is difficult to determine the actual extent of C. xerosis infections as reported in historic literature; however, modern sequencing and phenotypic analyses have allowed for more accurate identification of C. xerosis in clinical infections.
==== Congenital absence of vas deferens and seminal vesicle ==== In the male reproductive system, there are structures such as vas deferens and seminal vesicles which play an important role in transportation and production of semen or ejaculate. Abnormalities or absence of these structures can lead to low volume of semen and infertility in males. This condition can also be caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes for chloride channel protein.
Sources: en.wikipedia.org
Premier League: 1997–98, 2001–02, 2003–04 FA Cup: 1997–98, 2001–02, 2002–03, 2004–05, 2013–14, 2014–15, 2016–17; runner-up: 2000–01 FA Charity/Community Shield: 1998, 1999, 2002, 2004, 2014, 2015 2017 Football League/EFL Cup runner-up: 2006–07, 2010–11, 2017–18 UEFA Champions League runner-up: 2005–06 UEFA Cup runner-up: 1999–2000 Individual
The special forces site, located near a compound associated with Mullah Omar, was described as one of Akhundzada's most trusted units. Afghan locals also reported an airstrike in Spin Boldak District, while armed clashes resumed between Taliban forces and Pakistani border guards in Khost. However, a Taliban spokesperson claimed that no one had been hurt in the airstrikes and that they had caused only limited damage to a drug rehabilitation centre and an empty container. A police constable was injured while repelling a militant attack on a police post in Dera Ismail Khan District.
The RSP is also connected to the shaft via the pars intermedia (venous plexus of Kobelt). When engorged with blood, the bulbs cuff the vaginal opening and cause the vulva to expand outward. Although several texts state that they surround the vaginal opening, Ginger et al. state that this does not appear to be the case and tunica albuginea does not envelop the erectile tissue of the bulbs. In Yang et al.'s assessment of the bulbs' anatomy, they conclude that the bulbs "arch over the distal urethra, outlining what might be appropriately called the 'bulbar urethra' in women".
== Research trends == PPy is a potential vehicle for drug delivery. The polymer matrix serves as a container for proteins. Polypyrrole has been investigated as a catalyst support for fuel cells and to sensitize cathode electrocatalysts. Together with other conjugated polymers such as polyaniline, poly(ethylenedioxythiophene) etc., polypyrrole has been studied as a material for "artificial muscles", a technology that offers advantages relative to traditional motor actuating elements. Polypyrrole was used to coat silica and reverse phase silica to yield a material capable of anion exchange and exhibiting hydrophobic interactions. Polypyrrole was used in the microwave fabrication of multiwalled carbon nanotubes, a rapid method to grow CNT's. A water-resistant polyurethane sponge coated with a thin layer of polypyrrole absorbs 20 times its weight in oil and is reusable. The wet-spun polypyrrole fibre can be prepared chemical polymerization pyrrole and DEHS as dopant. Polypyrrole is often used as a coating material to accelerate synthetic mimics of cosmic dust into impact ionisation mass spectrometers, which are used on space missions to analyse the composition of their parent bodies.
=== Ceasefire attempts === Syrian minister of defense Murhaf Abu Qasra announced a ceasefire effective from 15 July 2025 after an agreement with the Druze leaders in Suwayda. The Syrian Ministry of Interior warned against any damage to private or public property in Suwayda. According to the ceasefire agreement, it was not a complete withdrawal of the administration, and it would be able to continue to maintain police forces in the district, which would operate together with local Druze, but it was required, as stated, to withdraw the military forces it had sent there in the battles in recent days. A mechanism was also agreed upon to regulate the issue of possession of heavy weapons in the area. The agreement also stipulates the establishment of an investigative committee that will examine atrocities committed by militants and regime members against the Druze, according to reports. Following the second ceasefire announced on 16 July 2025, Syrian president Ahmed al-Sharaa addressed the nation stating that the government's priority is to protect Druze citizens as Israel continues its assaults on Syria. He further said "we reject any attempt to drag you into hands of an external party. We are not among those who fear the war. We have spent our lives facing challenges and defending our people, but we have put the interests of the Syrians before chaos and destruction".
Sources: en.wikipedia.org
=== Italy === In Italy to become clinical or medical Biologist, you must achieve a BSc. and a MSc. in Biological Sciences and then four years of medical school of specialization in clinical Pathology ex general Pathology, ex Clinical biology.
The enzyme RNA polymerase binds to the exposed template strand and reads from the gene in the 3' to 5' direction. Simultaneously, the RNA polymerase synthesizes a single strand of pre-mRNA in the 5'-to-3' direction by catalysing the formation of phosphodiester bonds between activated nucleotides (free in the nucleus) that are capable of complementary base pairing with the template strand. Behind the moving RNA polymerase the two strands of DNA rejoin, so only 12 base pairs of DNA are exposed at one time. RNA polymerase builds the pre-mRNA molecule at a rate of 20 nucleotides per second enabling the production of thousands of pre-mRNA molecules from the same gene in an hour. Despite the fast rate of synthesis, the RNA polymerase enzyme contains its own proofreading mechanism. The proofreading mechanisms allows the RNA polymerase to remove incorrect nucleotides (which are not complementary to the template strand of DNA) from the growing pre-mRNA molecule through an excision reaction. When RNA polymerases reaches a specific DNA sequence which terminates transcription, RNA polymerase detaches and pre-mRNA synthesis is complete. The pre-mRNA molecule synthesized is complementary to the template DNA strand and shares the same nucleotide sequence as the coding DNA strand. However, there is one crucial difference in the nucleotide composition of DNA and mRNA molecules. DNA is composed of the bases: guanine, cytosine, adenine and thymine (G, C, A and T). RNA is also composed of four bases: guanine, cytosine, adenine and uracil.
Nanofibers are fibers with diameters in the nanometer range (typically, between 1 nm and 1 μm). Nanofibers can be generated from different polymers and hence have different physical properties and application potentials. Examples of natural polymers include collagen, cellulose, silk fibroin, keratin, gelatin and polysaccharides such as chitosan and alginate. Examples of synthetic polymers include poly(lactic acid) (PLA), polycaprolactone (PCL), polyurethane (PU), poly(lactic-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), and poly(ethylene-co-vinylacetate) (PEVA). Polymer chains are connected via covalent bonds. The diameters of nanofibers depend on the type of polymer used and the method of production. All polymer nanofibers are unique for their large surface area-to-volume ratio, high porosity, appreciable mechanical strength, and flexibility in functionalization compared to their microfiber counterparts. There exist many different methods to make nanofibers, including drawing, electrospinning, self-assembly, template synthesis, and thermal-induced phase separation. Electrospinning is the most commonly used method to generate nanofibers because of the straightforward setup, the ability to mass-produce continuous nanofibers from various polymers, and the capability to generate ultrathin fibers with controllable diameters, compositions, and orientations. This flexibility allows for controlling the shape and arrangement of the fibers so that different structures (i.e.
Model of Structure of Penicillin, by Dorothy Hodgkin et al., Museum of the History of Science, Oxford The Discovery of Penicillin, A government-produced film about the discovery of Penicillin by Sir Alexander Fleming, and the continuing development of its use as an antibiotic by Howard Florey and Ernst Boris Chain on YouTube. Penicillin at The Periodic Table of Videos (University of Nottingham) "Penicillin Released to Civilians Will Cost $35 Per Patient", Popular Science, August 1944, article at bottom of page Episode 2 (of 4): "Medical Drugs" of the BBC Four and PBS show: Extra Life: A Short History of Living Longer (2021)
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.